DTU
DTU

Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Emeritus Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240

Email:rury.holman@dtu.ox.ac.uk

ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.

Latest publications

Manuscript
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark et al.
ESC Heart Failure 2021

Manuscript
Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23)
Guang Ran Yang et al.
Sci Rep. 2021;11:9491

Manuscript
Cardiovascular and renal safety of metformin in patients with diabetes and moderate-to-severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials
Lindsay E. Clegg et al.
Diabetes Obes Metab. 2021;23:1101-1110

Manuscript
Predicting Major Adverse Limb Events in Individuals With Type 2 Diabetes: Insights From the EXSCEL Trial
E. Hope Weissler et al.
Diabetic Medicine 2021

Manuscript
Predicting the Risk of Developing Type 2 diabetes in Chinese People who have Coronary Heart Disease and Impaired Glucose Tolerance
Shishi Xu et al.
J Diabetes 2021

Manuscript
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension: A Systematic Review and Individual Participant-based Meta-analysis
Stephen P Juraschek et al.
Ann Int Med. 2020;174:58-68